In survival analysis, patients with a high stromal CD68+/FoxP3+ cell ratio (> 2.9) at the primary tumour site had a median survival of 32 months while those with a lower CD68+/FoxP3+ cell ratio (< 2.9) had a median survival of 55 months (p = 0.008) (graph not shown). The gene discussed is FOXP3; the disease is neoplasm.